# A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

> **NCT07332533** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 490 (estimated)

## Conditions studied

- HER2-positive Gastric Cancer

## Interventions

- **DRUG:** KN026
- **DRUG:** Capecitabine
- **DRUG:** Enlonstobart
- **DRUG:** Oxaliplatin
- **DRUG:** Trastuzumab
- **DRUG:** Pembolizumab
- **DRUG:** Cisplatin
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT07332533
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2032-06-30
- **Final completion:** 2032-12-31
- **Target enrollment:** 490 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07332533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07332533, "A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07332533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*